Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00352742Phase 1Terminated

A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

Role: lead

NCT00405574Phase 2Unknown

Study of ATN-224 in Patients With Prostate Cancer

Role: lead

NCT00131651Phase 2Terminated

ATN-161 in Advanced Renal Cell Cancer

Role: lead

NCT00383851Phase 2Unknown

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

Role: lead

All 4 trials loaded